Carcinoembryonic antigen (CEA) levels were measured with a CEA‐2 enzyme immune assay (EIA) kit (Elecsys CEAII; Roche Diagnostics K.K., Tokyo, Japan) following the manufacturer's instructions with a cut‐off value of 5.0 ng/mL.17 Cancer antigen 19‐9 (CA19‐9) levels were measured with a CA19‐9 EIA kit (Elecsys CA19‐9; Roche Diagnostics K.K.) with a cut‐off value of 37 U/mL.17
Elecsys ca19 9
Manufactured by Roche
Sourced in Japan
The Elecsys CA19-9 is an in vitro diagnostic test used to measure the levels of the CA19-9 tumor marker in human serum or plasma samples. CA19-9 is a carbohydrate antigen that is often elevated in certain types of cancer, particularly pancreatic cancer. The Elecsys CA19-9 assay provides quantitative results that can be used by healthcare professionals as an aid in the management of patients with known or suspected pancreatic cancer.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using elecsys ca19 9
1
Serum CEA and CA19-9 Measurement
2
Serum Biomarkers and Immunohistochemical Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum NSE (neuron specific enolase), CEA (carcinoembryonic antigen), and CA19-9 (carbohydrate antigen 19–9) were measured according to the instruction of the commercial test Elecsys® NSE (Roche Diagnostics GmbH, Catalogue Number: 12133113122), Elecsys® CEA (Roche Diagnostics GmbH, Catalogue Number: 11731645322) and Elecsys® CA19-9 (Roche Diagnostics GmbH, Catalogue Number: 12133113122). The assays for each marker are designed as sandwich assay based on the Streptavidin-Biotin-technology and they were measured quantitatively on a cobas® e601 platform (Roche Diagnostics GmbH). The cut-off value for NSE (15.2 ng/mL), CEA (5 ng/mL) and CA19-9 (37 U/mL) were determined based on the reference value used in clinical practice.
Immunohistochemical analysis for tissue CgA, Synaptophysin (Syn) and CD56 was performed on a 4 μm thick paraffin-embedded tissue sections according to standardized procedure. The primary antibody used was rabbit anti-Chromogranin A monoclonal antibody (ZA-0507, ZSGB-BIO, Beijing, China), rabbit anti- Synaptophysin monoclonal antibody (ZA-0506, ZSGB-BIO, Beijing, China) and mouse anti-CD56 monoclonal antibody (ZM-0057, ZSGB-BIO, Beijing, China). The results were graded from 0 to 3 according to intensity of staining (0, negative or trace; 1, weak; 2, moderate; 3, intense). Staining of ≥ 1 was considered positive.
Immunohistochemical analysis for tissue CgA, Synaptophysin (Syn) and CD56 was performed on a 4 μm thick paraffin-embedded tissue sections according to standardized procedure. The primary antibody used was rabbit anti-Chromogranin A monoclonal antibody (ZA-0507, ZSGB-BIO, Beijing, China), rabbit anti- Synaptophysin monoclonal antibody (ZA-0506, ZSGB-BIO, Beijing, China) and mouse anti-CD56 monoclonal antibody (ZM-0057, ZSGB-BIO, Beijing, China). The results were graded from 0 to 3 according to intensity of staining (0, negative or trace; 1, weak; 2, moderate; 3, intense). Staining of ≥ 1 was considered positive.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!